Dermassociates PC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$152,998	11
2024	Research	$142,799	7
2023	Research	$155,082	17
2022	Research	$35,448	7
2021	Research	$137,918	34
2020	Research	$86,945	21
2019	Research	$65,764	17

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $504,168 30 payments
Regeneron Pharmaceuticals, Inc. $206,204 64 payments
Vanda Pharmaceuticals Inc. $31,632 7 payments
Janssen Research & Development, LLC $16,643 3 payments
Amgen Inc. $8,609 2 payments
LEO Pharma AS $7,513 2 payments
Sanofi US Services Inc. $1,456 4 payments
Genzyme Corporation $728 2 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata $161,423 2 payments
A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged >=6 Months to <6 Years With Severe Atopic Dermatitis $87,227 20 payments
A Phase 3 Double-Blind Randomized Placebo-Controlled Trial to Evaluate the Efficacy Safety and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata $76,884 1 payment
A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $48,524 5 payments
An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis Previously Treated With Dupilumab $41,682 2 payments
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-To-Severe Atopic Dermatitis $39,927 3 payments
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Patients With Moderate-To-Severe Atopic Dermatitis $37,761 3 payments
Evaluating the Effects of Tradipitant Vs. Placebo in Atopic Dermatitis $31,632 7 payments
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis $30,182 11 payments
An Open-Label, Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis Previously Treated With Dupilumab $29,359 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.